Dr. Véronique Suttels discusses her work on improving tuberculosis (TB) diagnostics in low-resource settings through AI-assisted lung ultrasound (LUS). In this Future Leaders interview, Dr Suttels outlines the potential challenges of implementing diagnostic tools like CAD LUS4TB across multiple countries and reflects on the role of technology in addressing diagnostic gaps. Her research highlights both the potential and limitations of AI in advancing equitable, scalable solutions for global TB control.
Back in February 2025, the 7th Forum on Respiratory Tract Infections (RTI) took place at the iconic Glasgow Science Centre - a fitting venue for a scientific conference built on innovation, collaboration and ground-breaking research. Each year RTI continues to grow ...
As part of our Future Leaders series, we spoke with Dr Amy Wolfe, Director of the LSUHSC-Wetmore TB Clinic and Assistant Professor of Medicine at LSUHSC in New Orleans. A specialist in pulmonary and critical care medicine, Dr Wolfe shares how her early experiences in post-Katrina New Orleans inspired her focus on health equity. She discusses the challenges of treating TB in underserved communities, the importance of wraparound care, and promising innovations in pulmonology—from AI-based diagnostics to expanded access to pulmonary rehabilitation and lung cancer screening.
As part of our Future Leaders series, Dr Debasree Banerjee, Assistant Professor at Brown University, shares her journey in pulmonary and critical care medicine (PCCM), highlighting its dynamic, collaborative nature. Passionate about equity, her research addresses how race and racism impact care. Dr Banerjee emphasizes perseverance, multidisciplinary collaboration, and inspiring future physicians through advocacy and meaningful patient connections.
As part of our Future Leaders series, we speak with Dr Helen Gavillet, a post-doctoral researcher at Northumbria University (UK) and Rising Star at RTI 2025. Dr Gavillet's research focuses on the lung microbiome in cystic fibrosis, particularly bacterial and fungal dynamics. Her research also examines the impact of CFTR modulators like elexacaftor/tezacaftor/ivacaftor on respiratory microbiota.
On April 24, 2025, Brussels will host the 4th annual Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day, organized by EUFOREA. This year’s theme, "New Ambitions of Care," focuses on enhancing understanding of CRSwNP, improving early diagnosis, and promoting better treatment strategies for those affected by this debilitating condition.
As part of our Future Leaders series, Dr. Shelby MacRae, a pulmonary and critical care specialist at LSUHSC, shares her journey from ICU intern to bronchiectasis and NTM researcher. She discusses challenges in care, lack of awareness, and future advances. Passionate about mentorship, she encourages future pulmonologists to find balance, build foundations, and stay driven by patient needs.
The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.
In this episode, Professor Irene Higginson, Director of Better Health and Care Futures at King’s College London, discusses the complex challenges of managing breathlessness. She explores non-pharmacological strategies, the value of multidisciplinary care, and how the Breathlessness Support Services at KCL are transforming patient support. Tune in for expert insights and a look at future directions in breathlessness research and care.
Brisbane, Australia, will host the 8th World Bronchiectasis Conference (WBC) from 14-17th July 2025, bringing together healthcare professionals, researchers and patients from around the globe to advance the understanding and treatment of bronchiectasis. The event is co-hosted by Lung Foundation Australia, the University of Queensland, and the Australian Bronchiectasis Consortium.
In this interview, Professor Juzar Ali, MD, FRCP(C), FCCP, a leading expert in respiratory medicine and LSU Alumni Klein Professor Emeritus of Medicine at Louisiana State University (LSU) Health Sciences Center in New Orleans, LA, USA, reflects on his distinguished career specializing in tuberculosis (TB), non-tuberculous mycobacterial disease (NTM) and bronchiectasis.
The 2025 AAAAI and WAO joint congress highlighted advances in chronic rhinosinusitis (CRS) treatment. Notable studies presented positive results for novel biologic therapies, including tezepelumab, depemokimab and mepolizumab for chronic rhinosinusitis with nasal polyps (CRSwNP), and dupilumab for chronic rhinosinusitis without nasal polyps (CRSsNP). These findings highlight significant advancements in symptom management, offering hope for improved patient outcomes and reduced treatment burdens.
We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.
Boehringer Ingelheim has announced that its investigational drug, nerandomilast (BI 1015550), has successfully met the primary endpoint in the phase III FIBRONEERâ„¢-ILD study. The trial assessed the absolute change from baseline in forced vital capacity (FVC) [mL] at Week 52 compared ...
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
As winter takes hold, the World Health Organisation (WHO) has begun sharing updates on pathogens and their impact across the Northern Hemisphere. This time of year is marked by a significant rise in acute respiratory infections (ARIs) and other common respiratory illnesses.
The results of a pivotal phase I/II study for PRGN-2012, an investigational gene therapy for recurrent respiratory papillomatosis (RRP), were recently published in The Lancet Respiratory Medicine.1 The study demonstrated that over 50% of participants achieved a complete response, requiring no surgical interventions for at least 12 months post-treatment. Additionally, the therapy showed a strong safety profile, with no dose-limiting toxicities reported. These findings form the basis of Precigen, Inc.’s Biologics License Application (BLA), which has been submitted to the U.S. Food and Drug Administration (FDA) along with a request for priority review. 1
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.